Unilife scores with sanofi-aventis
Tuesday, 01 July, 2008
Unilife Medical Solutions [ASX: UNI] has reached an agreement worth over $16 million with sanofi-aventis over licensing rights for Unilife's ready-to-fill syringe [RTFS].
In exchange for the $16.4 million license fee, sanofi-aventis will have exclusive rights to the product for a period of five years.
It is expected that a further agreement will be reached whereby sanofi-aventis will pay the industrialisation costs for the RTFS, which are estimated to total $24-27 million.
Unilife began pilot production of the RTFS units earlier this year, and full commercialisation of the product is expected to begin in 2011.
The RTFS is a pre-filled safety syringe with automatic, user-controlled needle retraction features to help prevent needlestick injuries.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
